MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$20,770K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from public offering of...
Maturities of investments
Accrued expenses (including rela...
Others
Negative Cash Flow Breakdown
Net loss
Issuance costs paid in connectio...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Operating expenses
-
-
89,810
-
Other income, net
-
-
5,945
-
Net loss
-25,005
-23,516
-20,772
-21,528
Depreciation and amortization
692
666
666
662
Stock-based compensation
1,865
1,593
1,589
1,631
Change in fair value of safes (including related party amounts of 0 and 2,911, respectively)
-
-
0
-
Accretion of discounts and amortization of premiums on investments, net
116
199
291
357
Accounts receivable (including related party amounts of 0 and 569, respectively)
-
-
0
-
Other receivables (including related party amounts of 61 and (30), respectively)
141
-67
-12
49
Prepaid expenses and other current assets
783
-2,633
-1,886
-194
Other long-term assets
351
-
40
380
Accounts payable (including related party amounts of 0 and (271), respectively)
-780
1,812
-150
-442
Accrued expenses (including related party amounts of 22 and (715), respectively)
4,020
-4,003
2,365
1,119
Operating lease right-of-use asset and lease liabilities, net
244
-3
9
-51
Net cash used in operating activities
-20,355
-20,950
-14,726
-19,201
Purchases of property and equipment
415
242
421
600
Purchases of investments
0
6,442
7,539
12,745
Maturities of investments
18,000
22,000
24,000
29,623
Net cash provided by investing activities
17,585
15,316
16,040
16,278
Proceeds from public offering of common stock and issuance of pre-funded warrants
300,000
-
-
-
Proceeds from issuance of common stock, net of commissions
-
-
0
-
Issuance costs paid in connection with public offering of common stock and issuance of pre-funded warrants
16,793
-
-
-
Proceeds from exercise of stock options
67
-
0
0
Proceeds from purchase of espp shares
-7
-131
0
-99
Payments to taxing authorities related to net-settlement of vested restricted stock units
0
210
87
104
Payments on finance leases
12
33
34
32
Cash paid in connection with ipo offering costs
-
-
0
-
Net cash provided by financing activities
283,269
-112
-121
-37
Net increase (decrease) in cash, cash equivalents and restricted cash
280,499
-5,746
1,193
-2,960
Cash, cash equivalents and restricted cash at beginning of period
21,416
27,162
25,969
40,493
Cash, cash equivalents and restricted cash at end of period
301,915
-
-
-
Cash and cash equivalents
301,454
-
-
-
Restricted cash
461
-
-
-
Total cash, cash equivalents and restricted cash
301,915
21,416
27,162
25,969
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from public
offering of common stock...
$300,000K
Maturities of investments
$18,000K
(-68.56%↓ Y/Y)
Proceeds from exercise of
stock options
$67K
(-51.45%↓ Y/Y)
Proceeds from purchase of
espp shares
-$7K
(94.78%↑ Y/Y)
Net cash provided by
financing activities
$283,269K
(169522.16%↑ Y/Y)
Net cash provided by
investing activities
$17,585K
(-43.44%↓ Y/Y)
Canceled cashflow
$16,805K
Canceled cashflow
$415K
Net increase
(decrease) in cash, cash...
$280,499K
(2525.62%↑ Y/Y)
Canceled cashflow
$20,355K
Issuance costs paid in
connection with public...
$16,793K
Payments on finance
leases
$12K
(-81.82%↓ Y/Y)
Accrued expenses
(including related party...
$4,020K
(371.44%↑ Y/Y)
Stock-based compensation
$1,865K
(-48.21%↓ Y/Y)
Depreciation and
amortization
$692K
(-45.47%↓ Y/Y)
Operating lease
right-of-use asset and lease...
$244K
(1061.90%↑ Y/Y)
Purchases of property and
equipment
$415K
(-73.50%↓ Y/Y)
Net cash used in
operating activities
-$20,355K
(52.47%↑ Y/Y)
Canceled cashflow
$6,821K
Net loss
-$25,005K
(39.84%↑ Y/Y)
Prepaid expenses and
other current assets
$783K
(-78.33%↓ Y/Y)
Accounts payable
(including related party...
-$780K
(-364.29%↓ Y/Y)
Other long-term
assets
$351K
(253.28%↑ Y/Y)
Other receivables
(including related party...
$141K
(221.55%↑ Y/Y)
Accretion of discounts and
amortization of premiums on...
$116K
(-90.58%↓ Y/Y)
Buy us a coffee
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)